ROIV Stock Analysis: Roivant Sciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 25.268m USD | 12M Return: 238.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 190M
Qual. Beats: 0
Rev. Trend: -95.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Roivant Sciences Ltd. (NASDAQ: ROIV) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in London, UK, that focuses on discovering, developing, and commercializing medicines. Its pipeline includes IMVT-1402, a monoclonal antibody targeting FcRn for IgG-mediated autoimmune indications; mosliciguat, its lead inhaled sGC activator for pulmonary hypertension associated with interstitial lung disease; batoclimab for thyroid eye disease; and brepocitinib, a TYK2/JAK1 inhibitor being studied in immune-mediated diseases such as dermatomyositis and non-infectious uveitis. The company also operates drug delivery platforms, including lipid nanoparticle (LNP) and ligand conjugate technologies.
As a clinical-stage biopharma, Roivant does not yet generate commercial product revenue and depends on capital markets to fund its R&D activities. The biotechnology sector is characterized by long development timelines, high clinical trial failure rates, and significant regulatory risk, with valuation typically driven by pipeline progress, partnership agreements, and milestone-based catalysts rather than current sales.
- Mosliciguat Phase 3 pulmonary hypertension data readout expected
- IMVT-1402 competes with Vyvgart in FcRn autoimmune space
- Cash burn and pipeline funding shape capital allocation strategy
| Net Income: -299.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.13 > 0.02 and ΔFCF/TA 3.64 > 1.0 |
| NWC/Revenue: 59.2k% < 20% (prev 19.0k%; Δ 40.2k% < -1%) |
| CFO/TA -0.13 > 3% & CFO -750.3m > Net Income -299.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 18.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (812.3m) vs 12m ago 14.84% < -2% |
| Gross Margin: 84.44% > 18% (prev 96.35%; Δ -11.91% > 0.5%) |
| Asset Turnover: 0.15% > 50% (prev 0.47%; Δ -0.32% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.85 (Total Current Assets 5.17b - Total Current Liabilities 281.2m) / Total Assets 5.73b |
| B: -0.09 (Retained Earnings -501.8m / Total Assets 5.73b) |
| C: -0.05 (EBIT TTM -264.6m / Avg Total Assets 5.58b) |
| D: 10.39 (Book Value of Equity 4.53b / Total Liabilities 435.6m) |
| Altman-Z'' = 15.90 = AAA |
| DSRI: 3.0 (Receivables 789.8m/143.8m, Revenue 8.26m/25.5m) |
| GMI: 1.14 (GM 96.35% / 84.44%) |
| AQI: 1.32 (AQ_t 0.08 / AQ_t-1 0.06) |
| SGI: 0.32 (Revenue 8.26m / 25.5m) |
| TATA: 0.08 (NI -299.8m - CFO -750.3m) / TA 5.73b) |
| Beneish M = -1.54 (Cap -4..+1) = CCC |
As of July 08, 2026, the stock is trading at USD 36.31 with a total of 6,065,986 shares traded. Over the past week, the price has changed by +4.55%, over one month by +27.45%, over three months by +30.85% and over the past year by +238.08%.
Current recommended Stop Loss: 34.90 (which is 3.9% or 1.2 ATR below the current price).
Roivant Sciences has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ROIV.
- StrongBuy: 6
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 39 | 7.5% |
P/S = 3059.0762
P/B = 5.5653
Revenue TTM = 8.26m USD
EBIT TTM = -264.6m USD
EBITDA TTM = -261.2m USD
Long Term Debt = 96.3m USD (estimated: total debt 107.4m - short term 11.1m)
Short Term Debt = 11.1m USD (from shortTermDebt, last quarter)
Debt = 107.4m USD (from shortLongTermDebtTotal, last quarter) (leases 107.4m already included)
Net Debt = -4.19b USD (calculated: Debt 107.4m - CCE 4.30b)
Enterprise Value = 21.1b USD (25.3b + Debt 107.4m - CCE 4.30b)
Interest Coverage Ratio = unknown (Ebit TTM -264.6m / Interest Expense TTM 0.0)
EV/FCF = -27.79x (Enterprise Value 21.1b / FCF TTM -758.6m)
FCF Yield = -3.60% (FCF TTM -758.6m / Enterprise Value 21.1b)
FCF Margin = -9.18k% (FCF TTM -758.6m / Revenue TTM 8.26m)
Net Margin = -3.63k% (Net Income TTM -299.8m / Revenue TTM 8.26m)
Gross Margin = 84.44% ((Revenue TTM 8.26m - Cost of Revenue TTM 1.28m) / Revenue TTM)
Gross Margin QoQ = 87.30% (prev 64.98%)
Tobins Q-Ratio = 3.68 (Enterprise Value 21.1b / Total Assets 5.73b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 107.4m)
Taxrate = 21.66% (98.4m / 454.1m)
NOPAT = -207.3m (EBIT -264.6m * (1 - 21.66%)) [loss with tax shield]
Current Ratio = 18.37 (Total Current Assets 5.17b / Total Current Liabilities 281.2m)
Debt / Equity = 0.02 (Debt 107.4m / totalStockholderEquity, last quarter 4.53b)
Debt / EBITDA = 16.03 (negative EBITDA) (Net Debt -4.19b / EBITDA -261.2m)
Debt / FCF = 5.52 (negative FCF - burning cash) (Net Debt -4.19b / FCF TTM -758.6m)
Total Stockholder Equity = 4.38b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.37% (Net Income -299.8m / Total Assets 5.73b)
RoE = -6.85% (Net Income TTM -299.8m / Total Stockholder Equity 4.38b)
RoCE = -5.92% (EBIT -264.6m / Capital Employed (Equity 4.38b + L.T.Debt 96.3m))
RoIC = -3.80% (negative operating profit) (NOPAT -207.3m / Invested Capital 5.46b)
WACC = 8.32% (E(25.3b)/V(25.4b) * Re(8.36%) + D(107.4m)/V(25.4b) * Rd(0.0%) * (1-Tc(0.22)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -49.44 | Cagr: -1.71%
[DCF] Fair Price = unknown (Cash Flow -758.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.17 | # QB: 0
Revenue Correlation: -95.07 | Revenue CAGR: -54.28% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.36 | Chg30d=-6.66% | Revisions=-40% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.40 | Chg30d=-4.95% | Revisions=-50% | Analysts=3
EPS current Year (2027-03-31): EPS=-1.50 | Chg30d=-29.06% | Revisions=-50% | GrowthEPS=-38.8% | GrowthRev=+844.0%
EPS next Year (2028-03-31): EPS=-1.56 | Chg30d=-20.35% | Revisions=-50% | GrowthEPS=-4.2% | GrowthRev=+525.5%
[Analyst] Revisions Ratio: -79% (up=0, down=11)